Invitation to conference call for updated results from the LYMRIT 37-01 Phase 1/2 trial, to be presented at ASH
(WorldNews Norway)

Oslo, Norway, 8 December 2017 Nordic Nanovector ASA (OSE: NANO) will host a conference call and audio cast on Monday 11 December at 08:00 CET to present the updated results from its ongoing LYMRIT 37-01 Phase 1/2 clinical study of Betalutin® in patients with relapsed/refractory (R/R) indolent non-Hodgkin`s lymphoma (iNHL). These results will be presented at the 59th Annual American Society of Hematology (ASH) meeting on 9-12 December 2017 in Atlanta, GA, USA. The poster will be published on Nordic Nanovector`s website (www.nordicnanovector.com) in the section:...